Overview Dividends

(CLB) Core Laboratories - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: NL0000200384

Reservoir Description, Production Enhancement

CLB EPS (Earnings per Share)

EPS Growth (3Y CAGR): 3.53%
EPS Trend (3Y Correlation): -7.2%

CLB Revenue

Revenue Growth (3Y CAGR): 1.95%
Revenue Trend (3Y Correlation): 39.7%

Description: CLB Core Laboratories October 23, 2025

Core Laboratories Inc. (NYSE: CLB) delivers reservoir description and production-enhancement services to oil- and-gas operators worldwide, operating through two segments: Reservoir Description, which characterizes rock and fluid samples to boost recovery, and Production Enhancement, which supplies well-completion, stimulation, and diagnostic solutions for improved well performance and EOR projects.

Key performance indicators from recent filings show FY 2023 revenue of roughly $1.1 billion with an operating margin near 14 %, while the company’s cash flow remains sensitive to upstream capital-expenditure cycles and oil-price volatility-core economic drivers that can swing demand for its laboratory and field services.

Sector-wide, CLB benefits from rising upstream spending on enhanced-oil-recovery techniques and carbon-capture initiatives, both of which are accelerating as regulators tighten emissions standards and producers seek to extend field life; however, a prolonged downturn in drilling activity could compress service pricing and utilization rates.

For a deeper quantitative view of CLB’s valuation relative to peers, the ValueRay platform offers a concise, data-driven dashboard worth checking.

CLB Stock Overview

Market Cap in USD	752m
Sub-Industry	Oil & Gas Equipment & Services
IPO / Inception	1995-09-20

CLB Stock Ratings

Growth Rating	-59.4%
Fundamental	64.5%
Dividend Rating	6.44%
Return 12m vs S&P 500	-38.2%
Analyst Rating	3.0 of 5

CLB Dividends

Dividend Yield 12m	0.26%
Yield on Cost 5y	0.22%
Annual Growth 5y	-38.52%
Payout Consistency	86.4%
Payout Ratio	5.2%

CLB Growth Ratios

Growth Correlation 3m	64.6%
Growth Correlation 12m	-69%
Growth Correlation 5y	-80.9%
CAGR 5y	-9.18%
CAGR/Max DD 3y (Calmar Ratio)	-0.14
CAGR/Mean DD 3y (Pain Ratio)	-0.29
Sharpe Ratio 12m	-1.66
Alpha	-45.35
Beta	1.383
Volatility	45.95%
Current Volume	335.6k
Average Volume 20d	708.5k
Stop Loss	14.4 (-5.8%)
Signal	-0.13

Piotroski VR‑10 (Strict, 0-10) 5.0

Net Income (32.1m TTM) > 0 and > 6% of Revenue (6% = 31.1m TTM)

FCFTA 0.08 (>2.0%) and ΔFCFTA 0.39pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 25.35% (prev 26.83%; Δ -1.49pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.08 (>3.0%) and CFO 49.7m > Net Income 32.1m (YES >=105%, WARN >=100%)

Net Debt (15.9m) to EBITDA (73.1m) ratio: 0.22 <= 3.0 (WARN <= 3.5)

Current Ratio 2.37 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (47.1m) change vs 12m ago -1.55% (target <= -2.0% for YES)

Gross Margin 17.12% (prev 17.56%; Δ -0.44pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 86.84% (prev 87.07%; Δ -0.23pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 5.17 (EBITDA TTM 73.1m / Interest Expense TTM 10.6m) >= 6 (WARN >= 3)

Altman Z'' 2.88

(A) 0.22 = (Total Current Assets 226.9m - Total Current Liabilities 95.7m) / Total Assets 591.4m

(B) 0.25 = Retained Earnings (Balance) 150.3m / Total Assets 591.4m

(D) -0.02 = Book Value of Equity -5.51m / Total Liabilities 314.0m

Total Rating: 2.88 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 64.52

1. Piotroski 5.0pt = 0.0

2. FCF Yield 5.90% = 2.95

3. FCF Margin 8.76% = 2.19

4. Debt/Equity 0.15 = 2.49

5. Debt/Ebitda 0.22 = 2.46

6. ROIC - WACC (= 0.64)% = 0.79

7. RoE 12.24% = 1.02

8. Rev. Trend 39.66% = 2.97

9. EPS Trend -7.22% = -0.36

What is the price of CLB shares?

As of November 08, 2025, the stock is trading at USD 15.29 with a total of 335,628 shares traded.
Over the past week, the price has changed by -4.14%, over one month by +23.58%, over three months by +48.68% and over the past year by -29.03%.

Is Core Laboratories a good stock to buy?

Neither. Based on ValueRay´s Fundamental Analyses, Core Laboratories is currently (November 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 64.52 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CLB is around 13.63 USD . This means that CLB is currently overvalued and has a potential downside of -10.86%.

Is CLB a buy, sell or hold?

Core Laboratories has received a consensus analysts rating of 3.00. Therefor, it is recommend to hold CLB.

Strong Buy: 0
Buy: 1
Hold: 3
Sell: 1
Strong Sell: 0

What are the forecasts/targets for the CLB price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	14	-8.4%
Analysts Target Price	14	-8.4%
ValueRay Target Price	15.5	1.4%

CLB Fundamental Data Overview November 05, 2025

Market Cap USD = 752.0m (752.0m USD * 1.0 USD.USD)
P/E Trailing = 23.75
P/E Forward = 19.7628
P/S = 1.4531
P/B = 2.1501
P/EG = 1.6717
Beta = 1.383
Revenue TTM = 517.5m USD
EBIT TTM = 54.7m USD
EBITDA TTM = 73.1m USD
Long Term Debt = 126.1m USD (from longTermDebt, last fiscal year)
Short Term Debt = 21.4m USD (from shortTermDebt, last fiscal year)
Debt = 41.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 15.9m USD (from netDebt column, last quarter)
Enterprise Value = 767.9m USD (752.0m + Debt 41.5m - CCE 25.6m)
Interest Coverage Ratio = 5.17 (Ebit TTM 54.7m / Interest Expense TTM 10.6m)
FCF Yield = 5.90% (FCF TTM 45.3m / Enterprise Value 767.9m)
FCF Margin = 8.76% (FCF TTM 45.3m / Revenue TTM 517.5m)
Net Margin = 6.21% (Net Income TTM 32.1m / Revenue TTM 517.5m)
Gross Margin = 17.12% ((Revenue TTM 517.5m - Cost of Revenue TTM 428.9m) / Revenue TTM)
Gross Margin QoQ = 19.35% (prev 17.51%)
Tobins Q-Ratio = 1.30 (Enterprise Value 767.9m / Total Assets 591.4m)
Interest Expense / Debt = 6.38% (Interest Expense 2.65m / Debt 41.5m)
Taxrate = 20.54% (3.75m / 18.3m)
NOPAT = 43.5m (EBIT 54.7m * (1 - 20.54%))
Current Ratio = 2.37 (Total Current Assets 226.9m / Total Current Liabilities 95.7m)
Debt / Equity = 0.15 (Debt 41.5m / totalStockholderEquity, last quarter 277.4m)
Debt / EBITDA = 0.22 (Net Debt 15.9m / EBITDA 73.1m)
Debt / FCF = 0.35 (Net Debt 15.9m / FCF TTM 45.3m)
Total Stockholder Equity = 262.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 5.43% (Net Income 32.1m / Total Assets 591.4m)
RoE = 12.24% (Net Income TTM 32.1m / Total Stockholder Equity 262.5m)
RoCE = 14.09% (EBIT 54.7m / Capital Employed (Equity 262.5m + L.T.Debt 126.1m))
RoIC = 11.43% (NOPAT 43.5m / Invested Capital 380.6m)
WACC = 10.79% (E(752.0m)/V(793.5m) * Re(11.11%) + D(41.5m)/V(793.5m) * Rd(6.38%) * (1-Tc(0.21)))
Discount Rate = 11.11% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.50%
[DCF Debug] Terminal Value 72.12% ; FCFE base≈44.7m ; Y1≈55.1m ; Y5≈94.0m
Fair Price DCF = 21.00 (DCF Value 977.6m / Shares Outstanding 46.6m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -7.22 | EPS CAGR: 3.53% | SUE: 1.90 | # QB: 1
Revenue Correlation: 39.66 | Revenue CAGR: 1.95% | SUE: 1.05 | # QB: 1

Additional Sources for CLB Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle